Jeanene Swanson

Blog Post

Acceleron Pharma Announces Discontinuation of Clinical Trials Program for CMT

By Jeanene Swanson | March 18, 2020
Blog Post

NS Pharma Launches Expanded Access Program for Viltolarsen

By Jeanene Swanson | March 9, 2020
Blog Post

Simply Stated: What is Inclusion-Body Myositis?

By Jeanene Swanson | February 28, 2020
Illustration of DNA
Blog Post

FDA Accepts NS Pharma’s NDA for Viltolarsen for the Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | February 26, 2020
Blog Post

MDA’s New Chief Research Officer Sharon Hesterlee Shares Vision for the Future

By Jeanene Swanson | February 21, 2020
Blog Post

Roche Genentech Announces Positive Results from Pivotal Study of Risdiplam in SMA Type 1

By Jeanene Swanson | January 31, 2020
Blog Post

Antisense Therapeutics Announces Positive Results from Phase 2 Study of ATL1102 in DMD

By Jeanene Swanson | January 24, 2020
Blog Post

MDA Awards More Than $1 Million in Venture Philanthropy Funding to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia

By Jeanene Swanson | January 13, 2020
Blog Post

FDA Approves ITF Pharma’s Tiglutik via PEG Tube for the Treatment of ALS

By Jeanene Swanson | December 20, 2019
Blog Post

Amylyx Pharmaceuticals Announces Positive Results from Phase 2 Study of AMX0035 for Treatment of ALS

By Jeanene Swanson | December 19, 2019